Corporate / M&A

Capital Markets

Financing and Investment Products

IP / IT

Data Protection

Employment and Executive Compensation

Competition

Regulatory

Vectivio

Homburger News

Share-Image Teamplate Deals-and-Cases

On May 22, 2023, VectivBio Holding AG (Nasdaq: VECT), Basel (Switzerland), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare gastrointestinal conditions, and Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced that they had entered into an agreement for Ironwood to launch an all-cash public tender offer to acquire all outstanding shares in VectivBio for USD 17 per share, with an estimated aggregate consideration of approximately USD 1 bn, net of VectivBio cash and debt. The acquisition price represents a premium of 80% relative to the volume-weighted average share price over the previous 90 trading days. The offer is subject to customary conditions and expected to close in mid-2023. VectivBio&#8217;s board of directors unanimously recommends the offer. Orbimed, Forbion and Versant Ventures, and VectivBio&#8217;s directors and officers jointly representing 28.6% of VectivBio&#8217;s shareholdings, entered into tender and support agreements in connection with, and in support of, the offer.
Homburger AG serves as legal and tax advisor to VectivBio on the transaction. The Homburger team includes Andreas Müller, Margrit Marti, Oliver Kneubühl, Francesco Bernasconi, Oliver Dalla Palma, Daniel Wenzinger and Carolina Rodriguez (all Corporate / M&amp;A), Lorenzo Togni (Capital Markets), Stefan Oesterhelt, Philippe Gobet and Kevin Müller (all Tax), Stefan Bindschedler (Financing and Investment Products), Luca Dal Molin (IP / IT; Data Protection), Angela Casey (Employment and Executive Compensation), and Richard Stäuber and Christoph Grüninger (Competition, Regulatory).

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Oerlikon

On December 16, 2022, OC Oerlikon Corporation AG, Pfäffikon (SIX: OERL), a global innovation powerhouse for surface engineering, polymer processing and additive manufacturing, announced that it has signed a definitive agreement to acquire Riri, a leading provider of coated metal accessories for the luxury fashion industry.
The transaction marks a milestone in Oerlikon’s growth strategy and diversifies Surface Solutions’ offerings and market access. The transaction is expected to close in the first quarter 2023, subject to regulatory approvals and standard closing conditions.
Homburger acts as transaction counsel to Oerlikon. The Homburger team advising Oerlikon is led by Daniel Hasler and comprises Karin Mattle, Francesco Bernasconi, Mike Lerchmüller, Julien Di Sabato (all Corporate / M&amp;A), Pietro Meineri (Litigation), Philippe Baumann (IP / IT), Dieter Grünblatt and Peter Müller (both Tax), Richard Stäuber and Daniel Lütolf (both Competition), and Giulia Menegon and Giovanni Dazio (both Employment and Executive Compensation).

Homburger advised OC Oerlikon on the acquisition of Riri 

On May 6, 2022, Global Blue Group Holding AG (NYSE: GB and GB.WS) announced that CK Opportunities Fund I, LP, an investment fund co-managed by Certares Opportunities LLC and Knighthead Opportunities Capital Management, LLC, has agreed to invest USD 225 m in Global Blue Group Holding AG. The investment in the leading global provider of tax-free shopping and payments solutions for international travelers will be used to support its future growth plans.
Of the investment, USD 180 m is in series B preferred shares and USD 45 m is in common shares. The new series B preferred shares will be issued at a price of USD 8.50 per share and will carry a 5% annual pay-in-kind dividend and are convertible into approximately 21 m common shares on a one-for-one basis. The USD 45 m investment in common shares will be issued at USD 5.24, translating into approximately 9 m common shares.
Homburger acted as Swiss counsel to Certares Opportunities LLC and Knighthead Opportunities Capital Management, LLC. The Homburger team was led by partner Dieter Gericke and included lead associate Carlo Sulser, associates Francesco Bernasconi and Isabelle Cordey, as well as junior associates Benjamin Camavdic and Thomas Leu (all Corporate / M&amp;A and Capital Markets), partners Dieter Grünblatt and Reto Heuberger, and associates Kevin Müller and Philippe Weber (all Tax), and Patrik Dudar (Employment and Executive Compensation).

Homburger advised Certares Opportunities LLC and Knighthead Opportunities Capital Management, LLC on their USD 225 m equity investment in Global Blue Group Holding AG

Francesco
Bernasconi

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Homburger advised OC Oerlikon on the acquisition of Riri

Homburger advised Certares Opportunities LLC and Knighthead Opportunities Capital Management, LLC on their USD 225 m equity investment in Global Blue Group Holding AG

Unzulässigkeit von erleichterten Fusionen nach Art. 23 Abs. 1 lit. b FusG bei indirekten Beteiligungsverhältnissen

Join the Team

Francesco Bernasconi

Career

Languages

Bar Registration

Teams

FrancescoBernasconi

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Homburger advised OC Oerlikon on the acquisition of Riri

Homburger advised Certares Opportunities LLC and Knighthead Opportunities Capital Management, LLC on their USD 225 m equity investment in Global Blue Group Holding AG

Unzulässigkeit von erleichterten Fusionen nach Art. 23 Abs. 1 lit. b FusG bei indirekten Beteiligungsverhältnissen

Join the Team

Francesco Bernasconi

Career

Languages

Bar Registration

Teams

Francesco
Bernasconi

Unzulässigkeit von erleichterten Fusionen nach Art. 23 Abs. 1 lit. b FusG bei indirekten Beteiligungsverhältnissen